Use of Antiplatelet Agents in Canadian Patients: A Reflection of the 2023 Antiplatelet Guidelines
DOI:
https://doi.org/10.58931/cct.2025.115Abstract
Antiplatelet agents play a fundamental role in secondary prevention of atherosclerotic cardiovascular disease by reducing the risk of recurrent ischemic events. Over the past decades, developments and refinements in antiplatelet therapy have been made through the commercialization of novel classes (P2Y12 inhibitors, glycoprotein [GP] IIb/IIIa inhibitors), modes of administration (oral and intravenous), and combination strategies (dual antiplatelet therapy [DAPT] of different durations). Recently, concerns have been raised regarding the prognostic impact of bleeding events associated with antiplatelet agents. Consequently, multiple strategies have been studied to optimize the fine balance between ischemic protection and bleeding avoidance with these agents. The 2023 Focused Update of the Guidelines for the Use of Antiplatelet Therapy by the Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology distilled the most recent evidence on this topic from a Canadian perspective. This review offers insights into the implementation of the guidelines’ recommendations in routine clinical practice within the Canadian setting.
References
Marquis-Gravel G, Robert-Halabi M, Bainey KR, Tanguay J-F, Mehta SR. The evolution of antiplatelet therapy after percutaneous coronary interventions: a 40-year journey. Can J Cardiol. 2022;38(10):S79-S88. doi:10.1016/j.cjca.2022.02.022 DOI: https://doi.org/10.1016/j.cjca.2022.02.022
Marquis-Gravel G, Dalgaard F, Jones AD, Lokhnygina Y, James SK, Harrington RA, et al. Post-discharge bleeding and mortality following acute coronary syndrome with or without PCI. J Am Coll Cardiol. 2020;76(2):162-171. doi:10.1016/j.jacc.2020.05.031 DOI: https://doi.org/10.1016/j.jacc.2020.05.031
Bainey KR, Marquis-Gravel G, Belley-Côté E, Turgeon RD, Ackman ML, Babadagli HE, et al. 2023 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy. Can J Cardiol. [published correction appears in Can J Cardiol. 2024 Jul;40(7):1367. doi: 10.1016/j.cjca.2024.05.001]. Can J Cardiol. 2024;40(2):160-181. doi:10.1016/j.cjca.2023.10.013 DOI: https://doi.org/10.1016/j.cjca.2024.05.001
Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay JF, et al. Pretreatment with prasugrel in Non–ST-segment elevation acute coronary syndromes. N Engl J Med. 2013;369(11):999-1010. doi: 10.1056/NEJMoa1308075 DOI: https://doi.org/10.1056/NEJMoa1308075
Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to ASA in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494-502. doi:10.1056/NEJMoa010746 DOI: https://doi.org/10.1056/NEJMoa010746
Lordkipanidzé M, Marquis-Gravel G, Tanguay J-F, Mehta SR, So DYF. Implications of the antiplatelet therapy gap left with discontinuation of prasugrel in Canada. CJC Open. 2021;3(6):814-821. doi:10.1016/j.cjco.2020.11.021 DOI: https://doi.org/10.1016/j.cjco.2020.11.021
Kim CJ, Park M-W, Kim MC, Choo EG, Hwant BH, Lee KY, et al. Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial. Lancet. 2021;398(10308):1305-1316. doi:10.1016/S0140-6736(21)01445-8 DOI: https://doi.org/10.1016/S0140-6736(21)01445-8
Cuisset T, Deharo P, Quilici J, Johnson TW, Deffarges S, Bassez C, et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J. 2017;38(41):3070-3078. doi:10.1093/eurheartj/ehx175 DOI: https://doi.org/10.1093/eurheartj/ehx175
Natsuaki M, Watanabe H, Morimoto T, Yamamoto K, Obayashi Y, Nishikawa R, et al. An ASA-free versus dual antiplatelet strategy for coronary stenting: STOPDAPT-3 randomized trial. Circulation. [published correction appears in Circulation. 2024 May 14;149(20):e1189-e1190. doi: 10.1161/CIR.0000000000001255]. Circulation. 2024;149(8):585-600. doi:10.1161/CIRCULATIONAHA.123.066720 DOI: https://doi.org/10.1161/CIR.0000000000001255
Lee S-Y, Jeong Y-H, Yun KH, Cho JY, Gorog DA, Angiolillo DJ, et al. P2Y12 inhibitor monotherapy combined with colchicine following pci in ACS patients: the MACT pilot study. JACC: Cardiovasc Interv. 2023;16(15):1845-1855. doi:10.1016/j.jcin.2023.05.035 DOI: https://doi.org/10.1016/j.jcin.2023.05.035
Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention. Circulation. 2019;140(3):240-261. doi:10.1161/CIRCULATIONAHA.119.040167 DOI: https://doi.org/10.1161/CIRCULATIONAHA.119.040167
Valgimigli M, Frigoli E, Heg D, Tijssen J, June P, Vranckx P, et al. Dual antiplatelet therapy after PCI in patients at high bleeding risk. N Engl J Med. 2021;385(18):1643-1655. doi:10.1056/NEJMoa2108749 DOI: https://doi.org/10.1056/NEJMoa2108749
Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. New Engl J Med. 2019;380(16):1509-1524. doi:10.1056/NEJMoa1817083 DOI: https://doi.org/10.1056/NEJMoa1817083
Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, et al. Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med. 2019;381(12):1103-1113. doi:10.1056/NEJMoa1904143 DOI: https://doi.org/10.1056/NEJMoa1904143
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Canadian Cardiology Today
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
